Magnetic Resonance Imaging (MRI) is pivotal in clinical diagnostics and neurological research, providing high-contrast, non-invasive imaging. However, the acquisition of high-resolution MRI is hampered by hardware limitations, extended scan durations, and low signal-to-noise ratios (SNR). To overcome these challenges, super-resolution (SR) techniques have emerged as a promising alternative, enhancing the resolution of low-resolution (LR) brain MRI images. This systematic review evaluates the current landscape of SR methods applied to brain MRI, analyzing recent studies’ algorithms, datasets, and evaluation metrics. We systematically retrieved and examined relevant literature from five major databases: Scopus, PubMed, IEEE Xplore, Google Scholar, and ACM Digital Library. Our analysis identifies key methodologies, including convolutional neural networks (CNNs), generative adversarial networks (GANs), and Transformer-based models, significantly contributing to SR advancements. The review also highlights the challenges in accurately reconstructing high-resolution images, particularly in maintaining fine details at higher scaling factors. Evaluation metrics such as Peak Signal-to-Noise Ratio (PSNR) and Structural Similarity Index (SSIM) are discussed to quantify the performance of these SR models. This comprehensive assessment provides insights into the current state of brain MRI SR, guiding future research and development efforts to improve diagnostic accuracy and reduce scan times.
This study aims to identify and evaluate a robust and replicable public health predictive model that can be applied to the COVID-19 time-series dataset, and to compare the model performance after performing the 7-day, 14-day, and 28-day forecast interval. The seasonal autoregressive integrated moving average (SARIMA) model was developed and validated using a Thailand COVID-19 open dataset from 1 December 2021 to 30 April 2022, during the Omicron variant outbreak. The SARIMA model with a non-statistically significant p-value of the Ljung–Box test, the lowest AIC, and the lowest RMSE was selected from the top five candidates for model validation. The selected models were validated using the 7-day, 14-day, and 28-day forward-chaining cross validation method. The model performance matrix for each forecast interval was evaluated and compared. The case fatality rate and mortality rate of the COVID-19 Omicron variant were estimated from the best performance model. The study points out the importance of different time interval forecasting that affects the model performance.
Background: CHIVID is a telemedicine solution developed under tight time constraints that assists Thai healthcare practitioners in monitoring non-severe COVID-19 patients in isolation programs during crises. It assesses patient health and notifies healthcare practitioners of high-risk scenarios through a chatbot. The system was designed to integrate with the famous Thai messaging app LINE, reducing development time and enhancing user-friendliness, and the system allowed patients to upload a pulse oximeter image automatically processed by the PACMAN function to extract oxygen saturation and heart rate values to reduce patient input errors. Methods: This article describes the proposed system and presents a mixed-methods study that evaluated the system’s performance by collecting survey responses from 70 healthcare practitioners and analyzing 14,817 patient records. Results: Approximately 71.4% of healthcare practitioners use the system more than twice daily, with the majority managing 1–10 patients, while 11.4% handle over 101 patients. The progress note is a function that healthcare practitioners most frequently use and are satisfied with. Regarding patient data, 58.9%(8,724/14,817) are male, and 49.7%(7,367/14,817) within the 18 to 34 age range. The average length of isolation was 7.6 days, and patients submitted progress notes twice daily on average. Notably, individuals aged 18 to 34 demonstrated the highest utilization rates for the PACMAN function. Furthermore, most patients, totaling over 95.52%(14,153/14,817), were discharged normally. Conclusion: The findings indicate that CHIVID could be one of the telemedicine solutions for hospitals with patient overflow and healthcare practitioners unfamiliar with telemedicine technology to improve patient care during a critical crisis. Clinical and Translational Impact Statement— CHIVID’s success arises from seamlessly integrating telemedicine into third-party application within a limited timeframe and effectively using clinical decision support systems to address challenges during the COVID-19 crisis.
Ritonavir-boosted lopinavir (LPV/r) has been recommended as an alternative regimen for HIV-naive patients who cannot tolerate nevirapine (NVP) and/or efavirenz (EFV). Although combinations of ritonavir and lopinavir have shown higher plasma concentration level of LPV in clinical settings, dosage adjustment is still required to maintain an adequate therapeutic efficacy and reduce side effects. A compartmental pharmacokinetic (PK) model of LPV/r was developed, including a mechanistic description of competitive inhibition. Systematic simulations were performed and predicted plasma drug concentration levels were compared with those from the literature. In particular, the simulated and experimental area under the curve (AUC) based on oral dosing were 76.10 μMol/L, and 76.25 μMol/L, respectively Results from the mathematical model support the hypothesis that the mechanism of LPV/r interaction is due to the competitive inhibition of CYP3A4 in the liver by ritonavir, resulting in an increasing LPV plasma concentration levels. The simulated plasma concentration-time courses were consistent with those from the literature with the goodness of fit (R 2 ) of 0.9025 (0.8269-0.9862 95%CI).
1 July 2013 in 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
Background: Lopinavir is a highly potent protease inhibitors commonly used in treatment of HIV infection. The drug has a very low bioavailability due to a rapid metabolism by cytochrome P450 3A (CYP3A) isoenzyme. We aimed to develop a biologically relevant pharmacokinetic model of lopinavir with a description of a CYP3A4-mediated first pass metabolism and enterohepatic circulation (EHC). Methods: A theoretical model of lopinavir was developed using the classical pharmacokinetic modeling concept. The model consisted of one compartment with first-order absorption from gastrointestinal (GI) depot and first-order clearance into recycling depot which incorporated into the model structure using ACSLX. Results: Lopinavir plasma concentration-time course was successfully simulated against a dataset from the literature. The model had an absorption rate constant (K a ) of 0.991 h -1 , a reabsorption rate constant (K reabsorb ) of 0.171 h -1 , and a volume of distribution (V/F) of 54.7 L. The 12 hours area under the concentration-time curve (AUC 0-12h ) values from our model simulation compares to the experimental data were 0.8141 μg/ml.h and 0.7058 μg/ml.h, respectively. Maximum plasma concentration of the drug (C max ) predicted from our model compare to the experimental data were 0.273 μg/ml and 0.442 μg/ml, respectively. While, minimum plasma concentration of the drug (C trough ) predicted from our model compare to the experimental data were similar at 0.0015 μg/ml. Conclusions: Modified one compartment with first-order absorption from gastrointestinal (GI) depot and first-order clearance into recycling depot describes a pharmacokinetic of oral single dose of lopinavir 400 mg. The model can also simulate a concentration-time course with a difference dosing and variable which can be used for further describing the pharmacology of the drug interaction when combine with the other drugs.